- Home
- SPRO vs GWH Comparison
SPRO vs GWH Comparison
Compare SPRO & GWH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- GWH
- Stock Information
- Founded
- SPRO 2013
- GWH 2011
- Country
- SPRO United States
- GWH United States
- Employees
- SPRO N/A
- GWH N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- GWH Industrial Machinery/Components
- Sector
- SPRO Health Care
- GWH Miscellaneous
- Exchange
- SPRO Nasdaq
- GWH Nasdaq
- Market Cap
- SPRO 45.7M
- GWH 39.6M
- IPO Year
- SPRO 2017
- GWH N/A
- Fundamental
- Price
- SPRO $0.72
- GWH $3.20
- Analyst Decision
- SPRO Buy
- GWH Hold
- Analyst Count
- SPRO 4
- GWH 5
- Target Price
- SPRO $5.00
- GWH $3.35
- AVG Volume (30 Days)
- SPRO 118.7K
- GWH 48.0K
- Earning Date
- SPRO 03-27-2025
- GWH 03-31-2025
- Dividend Yield
- SPRO N/A
- GWH N/A
- EPS Growth
- SPRO N/A
- GWH N/A
- EPS
- SPRO N/A
- GWH N/A
- Revenue
- SPRO $47,977,000.00
- GWH $6,241,000.00
- Revenue This Year
- SPRO N/A
- GWH $23.79
- Revenue Next Year
- SPRO N/A
- GWH $331.34
- P/E Ratio
- SPRO N/A
- GWH N/A
- Revenue Growth
- SPRO N/A
- GWH 31.11
- 52 Week Low
- SPRO $0.70
- GWH $2.92
- 52 Week High
- SPRO $1.81
- GWH $14.10
- Technical
- Relative Strength Index (RSI)
- SPRO 38.19
- GWH 39.40
- Support Level
- SPRO $0.75
- GWH $3.20
- Resistance Level
- SPRO $0.80
- GWH $3.57
- Average True Range (ATR)
- SPRO 0.05
- GWH 0.25
- MACD
- SPRO 0.00
- GWH 0.07
- Stochastic Oscillator
- SPRO 9.09
- GWH 16.00
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About GWH ESS Tech Inc.
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.